Remepy
Remepy is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Remepy.
Remepy is a company.
Key people at Remepy.
Key people at Remepy.
Remepy is a biotech startup pioneering Hybrid Drugs™, which combine traditional pharmaceuticals with AI-driven therapeutic software apps to deliver personalized, multimodal treatments for complex diseases. Their lead product, Hybridopa, targets Parkinson’s Disease (PD) by pairing Levodopa with adaptive digital protocols addressing motor skills, cognition, speech, sleep, stress, and comorbidities, regulated under FDA frameworks like SaMD-Drug combinations or PDURs.[1][2][5] Remepy serves PD patients and plans pharma partnerships for commercialization post-Phase III trials in H1 2026, while expanding to oncology and women's health; recent Phase II data showed significant UPDRS improvements and brain connectivity gains.[1][4]
The company solves the limitation of monotherapy drugs by standardizing synergistic biological-behavioral combos at scale, enhancing outcomes via daily AI-personalized interventions like motor, cognitive, and psychological training.[1][2] With strong clinical momentum—including a completed double-blind study—and a focus on reimbursement like pharma, Remepy positions itself as a leader in digital therapeutics, driving better patient results through regulated, adaptive prescriptions.[1][2]
Remepy emerged from the insight that many diseases, like PD, respond better to drug-non-drug combinations, but these lack standardization and scalability. Co-founders Dr. Michal Tsur (co-CEO) and Or Shoval (co-CEO) launched the company to create Hybrid Drugs™, integrating pharma with evidence-based digital protocols.[1][3] Key scientific backing comes from Prof. Amir Amedi (Chief Scientific Officer), leveraging neuroscience expertise in brain plasticity.[3][4]
Early traction includes the Butterfly study, a double-blind, placebo-controlled trial for Hybridopa that met its primary endpoint, improving UPDRS scores and thalamo-cortical connectivity—data shared at Biomed 2025.[1] This validated their model, paving the way for Phase III in H1 2026 and pharma partnerships.[1] Backed by high-profile advisors like former Israeli PM Naftali Bennett and Prof. Michal Schwartz (neuroimmunology pioneer), Remepy has evolved from PD focus to a platform for multiple hybrid drugs.[3]
Remepy rides the digital therapeutics and AI-health convergence trend, where software augments pharma for precision medicine amid aging populations and chronic disease burdens like PD (affecting motor/cognitive decline).[1][2][4] Timing aligns with FDA's PDURs framework, enabling regulated drug-software claims and reimbursement parity with pharma—unlocking market access as digital health matures post-COVID telehealth boom.[2]
Market forces favor Remepy: rising demand for combo therapies (biological + behavioral), AI advancements in personalization (e.g., predictive analytics), and pharma's need for differentiation via hybrid models.[1][4] By validating digital protocols clinically, Remepy influences the ecosystem—pushing standards for hybrid regulation, inspiring pharma partnerships, and accelerating neurotech for brain repair/immune modulation, potentially reshaping neurology and beyond.[1][3][5]
Remepy is primed for breakout with Hybridopa's Phase III launch in H1 2026 and pharma deals, leveraging Phase II wins to secure partnerships and funding. AI enhancements (e.g., NLP for patient monitoring) and platform expansion to oncology/women's health will drive growth amid regulatory tailwinds like PDURs.[1][4] Trends like AI-driven personalization and hybrid reimbursement will amplify their edge, evolving Remepy from PD pioneer to multi-disease platform leader—influencing how pharma integrates digital for superior, scalable outcomes.[2][3] This fusion of drugs and apps heralds a new era, making Remepy's vision of accessible, synergistic care a reality.
